Clinical issues in inhibitors

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 54-60

  Astermark, J ^a   Santagostino, E ^b   Keith Hoots, W ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Factor VIII bypassing activity; Factor VIII inhibitors; Haemophilia A; Immune tolerance induction

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

BRAIN HEMORRHAGE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG HALF LIFE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; MORBIDITY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS; HUMANS; IMMUNE TOLERANCE;

EID: 77955026316     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02294.x     Document Type: Review

References (65)

1. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004, 10(Suppl. 2):3-9.
2. Váradi K, Negrier C, Berntorp E. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003, 1:2374-80.
3. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006, 124:747-57. Epub 2006 May 12
4. Villar A, Aronis S, Morfini M. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10:352-9.
5. Astermark J, Donfield SM, DiMichele DM. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109:546-51. Epub 2006 Sep 21
6. Donfield SM, Astermark J, Lail AE, Gilbert SA, Berntorp E. Value added: increasing the power to assess treatment outcome in joint haemorrhages. Haemophilia 2008, 14:276-80. Epub 2008 Jan 8
7. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008, 14:287-94. Epub 2007 Dec 10
8. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981, 305:717-21.
9. Hilgartner MW, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990, 30:626-30.
10. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996, 26(Suppl. 1):135-8.
11. Negrier C, Goudemand J, Sultan Y. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997, 77:1113-9.
12. Key NS, Aledort LM, Beardsley D. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998, 80:912-8.
13. Lusher JM, Roberts HR, Davignon G. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998, 4:790-8.
14. Arkin S, Blei F, Fetten J. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000, 11:255-9.
15. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000, 11(Suppl. 1):S45-9.
16. Shirahata A, Kamiya T, Takamatsu J. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors. Int J Hematol 2001, 73:517-25.
17. Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006, 12:352-62.
18. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005, 11:100-6.
19. Kavakli K, Makris M, Zulfikar B. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006, 95:600-5.
20. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006, 4:367-71.
21. Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience. Haemophilia 2009, 15:727-32.
22. Klintman J, Berntorp E, Astermark J. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Haemophilia 2009, Oct 30 [Epub ahead of print]
23. Bolliger D, Szlam F, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Haemophilia 2010 Mar 29, 103(6). [Epub ahead of print]
24. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002, 22:1381-9.
25. Mackman N. The many faces of tissue factor. J Thromb Haemost 2009, 7(Suppl. 1):136-9.
26. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989, 134:1087-97.
27. Shetty S, Vora S, Kulkarni B. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007, 138:541-4.
28. Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006, 134:314-9.
29. Astermark J, Ekman M, Berntorp E. Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors. Br J Haematol 2002, 119:342-7.
30. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994, 94:1496-505.
31. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007, 13:244-8.
32. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009, 15:904-10.
33. Teitel J, Berntorp E, Collins P. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007, 13:256-63.
34. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007, 13(Suppl. 1):1-22.
35. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors. A systematic review. Haemophilia 2003, 9:436-63.
36. DiMichele D, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006, 4:2271-3.
37. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007, 13(Suppl. 5):73-7.
38. Mariani G, Kroner B. Immune tolerance in hemophilia with inhibitors: predictors of success. Haematologica 2001, 86:1186-93.
39. DiMichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009, 15:320-8.
40. Lenk H. The German registry of immune tolerance treatment in hemophilia - 1999 update. Haematologica 2000, 85:45-7.
41. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999, 77(Suppl. 1):33-7.
42. Coppola A, Margaglione M, Santagostino E. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of patients with severe hemophilia A and high-responding inhibitors. J Thromb Haemost 2009, 7:1809-15.
43. Hay CRM, Goldberg I, Foulkes M, DiMichele DM. International prospective randomized immune tolerance (ITI) study: interim analysis of therapeutic efficacy and safety. Haemophilia 2010, 16:405. (abstract P5)
44. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years''Bonn protocol'. Vox Sang 1996, 70(Suppl. 1):30-5.
45. Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2009, December 16. [Epub ahead of print]
46. Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010, 16(Suppl. 2):16-23.
47. Kreuz W, Escuriola-Ettingshausen C, Auerswald G, Heidemann P, Kemkes-Matthes B, Schneppenheim R. Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Haematologica 2001, 86(Suppl. 4):16-20.
48. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand concentrates in the treatment of hemophilia A patients. Haematologica 2003, 88(Suppl. 9):21-5.
49. Gringeri A, Musso R, Mazzucconi MG. Immune tolerance induction with a high-purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007, 13:373-9.
50. Kurth MA, DiMichele D, Sexauer C. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008, 14:50-5.
51. Grenninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008, 14:295-302.
52. Astermark J, Morado M, Rocino A. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006, 12:363-71.
53. Carcao M, St Louis J, Poon M-C. Rituximab for congenital hemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006, 12:7-18.
54. Collins PW, Mathias M, Hanley J. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 2009, 7:787-94.
55. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009, 7:1446-56.
56. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007, 357:535-44.
57. Brackmann HH. Induced immune tolerance in Factor VIII inhibitor patients. Prog Clin Biol Res 1984, 150:181-95.
58. Kreuz W, Escuriola-Ettinghausen C, Martinez I. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood 2000, 96:266a.
59. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa inhaemophilia patients within inhibitors. Haemophilia 2005, 11:203-7.
60. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term prophylaxis with FEIBA does not prevent progression of existing joint disease. Haemophilia 2003, 9:261-8.
61. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex conscentrate (FEIBA) reduces the fregquency of bleeding episodes in paediatricpatients with haemophilia A and inhibitors. Haemophilia 2007, 13:249-55.
62. Konkle BA, Ebbesen LS, Erhardtsen E. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in haemophilia patients with inhibitors. J Thromb Haemost 2007, 5:1904-13.
63. Hoots WK, Ebbesen LS, Konkle BA. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008, 14:466-75.
64. Gringeri A, Nantovani LG, Scalone L, Mannuccci PM. Cost of care and quality of life for patients with haemophilia complicated by inhibitors. Blood 2003, 102:2358-63.
65. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Haemophilia 2006, 12(Suppl. 6):74-80.